✦ LIBER ✦

P.2.024 Mirtazapine augmentation in treatment-resistant major depressive disorder: an open-label, six-week trial

Book ID: 118591795
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 241 KB
Volume: 15
Category: Article
ISSN: 0924-977X
DOI: 10.1016/s0924-977x(05)80813-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Riluzole Augmentation in Treatment-Resis

Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial

✍ Vladimir Coric; Sarper Taskiran; Christopher Pittenger; Suzanne Wasylink; Daniel 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 132 KB

Efficacy and tolerability of mirtazapine

Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial

✍ J. E. Kim; S. J. Yoon; J. Kim; J. Y. Jung; H. S. Jeong; H. B. Cho; E. Shin; I. K 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB

Escitalopram in the treatment of major d

Escitalopram in the treatment of major depressive disorder: An open-label naturalistic trial in various settings

✍ L. Hranov⁎; I. Staleva 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 65 KB

Escitalopram in the treatment of major d

Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial

✍ Pratap Chokka; Mark Legault 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views

Effectiveness and tolerability of paroxe

Effectiveness and tolerability of paroxetine controlled release (CR) in the treatment of major depressive disorder: an open-label, prospective, multi-center trial in Korea

✍ Chi-Un Pae; Won-Myong Bahk; Duk-In Jon; Sang-Yeol Lee; Bo-Hyun Yoon; Kyung Joon 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 2 views

## Abstract ## Objectives This study evaluated the effectiveness and tolerability of paroxetine controlled release (CR) for the treatment of Korean patients with major depressive disorder (MDD) in a naturalistic treatment setting. ## Methods One hundred and ninety patients with MDD were enrolled